XTLB (XTL Biopharmaceuticals) Goodwill: $0.00 Mil (As of Jun. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
24 GF Score
Price $2.35
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Goodwill?

XTL Biopharmaceuticals XTLB -7.99% 24 Goodwill is $0.00 Mil as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. XTL Biopharmaceuticals's goodwill for the quarter that ended in Jun. 2025 was $0.00 Mil.


XTL Biopharmaceuticals  (NAS:XTLB) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

XTL Biopharmaceuticals's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Goodwill-to-Asset (A: Dec. 2024 )=Goodwill/Total Assets
=3.193/8.55
=0.37

XTL Biopharmaceuticals's Goodwill-to-Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

Goodwill-to-Asset (Q: Jun. 2025 )=Goodwill/Total Assets
=0/0.714
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


XTL Biopharmaceuticals Goodwill Related Terms


XTL Biopharmaceuticals Goodwill Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Goodwill Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Goodwill
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.19

XTL Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.19 0.00
XTLB
24GF Score
XTL Biopharmaceuticals Ltd XTLB
Goodwill is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

Frequently Asked Questions Learn more about Goodwill →
What does a Goodwill of $0.00 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Goodwill of $0.00 Mil as of Jun. 2025. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Goodwill too high?
XTL Biopharmaceuticals' current Goodwill is $0.00 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Goodwill compare to VRTX and REGN?
XTL Biopharmaceuticals' Goodwill of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill for a Biotechnology company?
A good Goodwill depends on the Biotechnology industry context. However, Goodwill should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill mean?
A high Goodwill can signal that a stock is expensive relative to its fundamentals. Goodwill is the intangible assets representing the value in excess of the acquired company's value. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Goodwill is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Goodwill of $0.00 Mil. The current Goodwill is $0.00 Mil. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill calculated?
Goodwill is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Goodwill is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score

Get the complete analysis for XTLB

Goodwill is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.35
Price